If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Keep me logged in Forgot your password?

Please wait...

Please wait...

 Diabetic Nephropathy

ESRD More Likely than Death for Patients with Diabetic Nephropathy

December 07, 2011

Patients with type 2 diabetic nephropathy are more likely to progress to end-stage renal disease (ESRD) than die, according to investigators.
 

Pirfenidone May Help Treat Diabetic Nephropathy

May 13, 2011

An anti-fibrotic and anti-inflammatory drug called pirfenidone may help treat diabetic nephropathy, according to a new randomized, double-blind study.
 

New Agent May Prevent Diabetic Nephropathy

April 14, 2011

Utah researchers report success with a new agent for preventing diabetic nephropathy. The agent is called atrasentan and it is a highly selective endothelin-A receptor (ETAR) agonist.
 

Greater Risk of Nephropathy in Hypertensive Diabetes Reported

January 05, 2011

ACE inhibitor of ARB use decreased progression risk in patients with macroalbuminuria at baseline.
 

Podocytes May Need Insulin to Maintain Kidney Function

November 15, 2010

Podocytes demonstrate a strong reliance on insulin to function properly, according to a study published in Cell Metabolism (2010;12:329-340).
 

UACR Varies by Season in Diabetic Nephropathy

November 15, 2010

Researchers have found a seasonal variation in urinary albumin-to-creatinine ratio (UACR) in Japanese patients with type 2 diabetes and early nephropathy, with the highest values in winter and the lowest in summer.
 

Morning Urine Test Better For Renal Risk Assessment

September 24, 2010

The albumin:creatinine ratio in the first urine excreted in the morning is better than 24-hour urinary albumin excretion in determining the risk for renal events in patients with type 2 diabetes and nephropathy, data show.
 

Vitamin B Could Have a Down Side in Patients with Diabetic Nephropathy

May 14, 2010

Patients with diabetic nephropathy should avoid taking high doses of B vitamins to lower homocysteine levels.
 

New Biomarkers of Diabetic Nephropathy

October 22, 2009

Cell adhesion molecules may be potential targets for therapeutic intervention to delay CKD progression.
 

Megadosage Candesartan Beneficial

February 18, 2009

Renal disease patients who have persistent proteinuria despite treatment with the highest approved dosage of the angiotensin receptor blocker candesartan may benefit from higher dosages, a Canadian study finds.
 

Predictors of Cardiac Events After Renal Transplantation

November 01, 2008

Diabetic nephropathy and CVD prior to renal transplantation are the most important predictors of post-transplant cardiovascular events, researchers in The Netherlands conclude.
 

U.K. Team: GFR Estimates Important

September 01, 2008

SAN FRANCISCO—British researchers have endorsed U.S. guidelines stating that screening diabetic patients for renal disease should involve estimated glomerular filtration rate (eGFR) in addition to testing for albuminuria.
 

Renoprotective Effect of Aliskiren Shown

July 24, 2008

Aliskiren, an oral direct renin inhibitor, may have renoprotective effects that are independent of its BP-lowering effect in patients with type 2 diabetic nephropathy who are receiving the maximal recommended renoprotective treatment and optimal antihypertensive therapy, researchers report.
 

Intensive Glucose Control Found to Protect Kidneys

June 10, 2008

Intensive glucose control with gliclazide (modified release) and other agents reduced the risk of nephropathy by one fifth in a large study of patients with type 2 diabetes.
 

Tighter Glycemic Control Beneficial

December 01, 2007

Better glucose management can reduce mortality and morbidity in dialysis patients.
 

More Type 2 Diabetics Face ESRD

October 23, 2007

End-stage renal disease (ESRD) is affecting a growing proportion of type 2 diabetics in Australia and New Zealand, a study found.
 

Telmisartan Offers Better Renoprotection

July 01, 2007

CHICAGO—Telmisartan (Micardis HCT), a novel angiotensin receptor blocker (ARB), and the older ARB losartan have similar BP-lowering efficacy in hypertensive patients with diabetic nephropathy, but treatment with the new agent is associated with larger reductions in proteinuria, new findings show.
 

Mechanisms of Diabetic Nephropathy

April 24, 2007

The kidney consists of four basic tissue types: vessels, glomeruli, tubules, and interstitium. Each of these types may be influenced by different pathophysiologic mechanisms associated with diabetic nephropathy. Despite their variability, these mechanisms share common clinical outcomes including microalbuminuria, progesssion to end-stage renal disease, and increased risks of cardiovascular morbidity and mortality.
 

Benefits of Glycemic Control Unclear

January 01, 2007

Conflicting findings emerge on the link between HbA1c and mortality in diabetics on dialysis.
 

Spironolactone Beneficial In Type 2 Diabetic Nephropathy

December 01, 2006

Adding spironolactone to an ACE inhibitor or angiotensin II receptor blocker (ARB) is associated with a marked and sustained antiproteinuric effect in type 2 diabetics, researchers in the Netherlands found.
 

Diabetic Nephropathy Care Is Lacking

November 01, 2006

Kidney disease linked to diabetes, hypertension, and obesity is increasing throughout the world. It is estimated that diabetes leading to end-stage renal disease (ESRD) accounts for 40% of the patients who require kidney transplants in the United States, Europe, Japan, Australia, and New Zealand.
 

Enlarged Kidneys Predict Nephropathy

November 01, 2006

Renal hypertrophy is a major factor in the development of diabetic nephropathy in patients with type 1 diabetes.
 

Heart Screening Justified In Diabetic Nephropathy Patients

November 01, 2006

Patients with diabetic nephropathy who are candidates for kidney or kidney- pancreas transplantation should be screened routinely with coronary angiography, researchers in Norway conclude.
 

Further Data on Diabetic Retinopathy Drug Requested

October 01, 2006

Eli Lilly and Company has received an approvable letter from the FDA requesting additional supporting data for its new drug application for ruboxistaurin mesylate (proposed trade name: Arxxant), Lilly's investigational oral therapy for diabetic retinopathy.
 
Popular Topics
Acute Kidney Injury AKI Androgen Deprivation Anemia Benign Prostatic Hyperplasia Bladder Cancer BPH Cardiovascular Disease Chronic Kidney Disease Circumcision CKD CVD Dialysis End-stage Renal Disease Hemodialysis Hyperphosphatemia Kidney Cancer Overactive Bladder Prostate Cancer Renal Cell Carcinoma Reproductive Medicine Secondary Hyperparathyroidism Transplantation Urinary Incontinence Urology

 

© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions